News

Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.

 

MCWF Helps Improve Pregnancy per Embryo Transfer in Dairy Recipients with One Lactation

An abstract has been presented at the 2023 AETA & CETA/ACTE Joint Convention in Orlando, FL summarizing a study showing a positive effect of MCWF (Amplimune) on pregnancy per embryo transfer for dairy cows with one lactation.

beef calf with cow in a field

MCWF (Amplimune) Offers an Alternative for Herd Health as FDA Further Restricts Antibiotics

Effective in June, 2023, all over-the-counter bovine antibiotics in the U.S. will be switched to prescription-only status. Amplimune immunotherapy offers an alternative to antibiotics that does not require a prescription.

Feedlot Safety Study with Amplimune® Published in the Australian Veterinary Journal

A paper has been published in the Australian Veterinary Journal, “The innate immune stimulant Amplimune® is safe to administer to young feedlot cattle”, summarizing a research study conducted by CSIRO.

MCWF (Amplimune) Significantly Improves Fertility and Decreases Clinical Mastitis and Metritis in Organic-Certified Dairy Herd

In a newly published study, the incidence rates of both clinical mastitis and metritis before 28 days in milk were lower, and pregnancy rates (3 time points) were higher in Amplimune-treated cows vs. placebo-treated controls.

Amplimune® Now Available in New Zealand

NovaVive's immunotherapy for calf scours - Amplimune® - is now available in the New Zealand market. The product was approved for sale by Agricultural Compounds and Veterinary Medicines (ACVM) last September.

3 calves in a field

MCWF Greatly Improves Pregnancy Success in Heifer Embryo Transfer Recipients

An abstract being presented at the 2021 IETS Virtual Conference summarizes data from a study showing 45% of Amplimune-treated embryo transfer recipient heifers achieved pregnancy at Day 60 vs. 28% of untreated controls.

Sign up to stay up-to-date with NovaVive news.